Aug 12, 2025
FDA Expands Teva’s AJOVY As First Anti-CGRP Preventive For Pediatric Episodic Migraine Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced that the FDA has approved AJOVY (fremanezumab-vfrm) for the preventive treatment of episodic migraine in children and adolescents aged 6–...
Read More...
Nov 29, 2021
Migraine is the most commonly encountered disabling disorder that can be featured as attacks of severe, unilateral, and a pulsating form of headache composed of symptoms such as photophobia, phonophobia, nausea, vomiting, and cutaneous allodynia. As per the Migraine Research Foundation 2021, Migraine is considered ...
Read More...
Jun 09, 2021
Migraine is a medical condition characterized by recurrent headaches that can last from 4 to 72 hours and often results in a wide range of symptoms. It is mainly associated with a painful headache, however, the affected person may experience nausea, vomiting, disturbed vision, sensitivity to light, sound, and smell...
Read More...
Discover How Learning Disability Treatment Landscape is Evolving with the Emergence of Digital Assistant Technologies
Jul 04, 2025
A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray
Jun 10, 2025
LEQEMBI: A New Hope for Alzheimer’s Disease Patients
Feb 12, 2025
Newsletter/Whitepaper